|

New Players, New Studies & Financial Results [MindMed, CMPS, NUMI, TRUFF & WESA]

ByPsychedelic Spotlight

Researchers personally trying MDMA, a new company on the block, financial results for MindMed (MMED / MNMD / MMQ) & Compass Pathways (CMPS) & news on Numinus Wellness (NUMI) & Red Lights Holland (TRIP/TRUFF), this is what we will be covering in today’s episode.

Timestamps:
0:00 – Intro
0:18 – FDA clears researchers to test MDMA on themselves
1:55 – MindMed (MMED / MNMD) announces Q1 Financials
4:30 – Compass Pathways (CMPS) announces Q1 Financials
6:56 – Numinus Wellness (NUMI) supplies psilocybin extract to Optimi Health
8:17 – Red Light Holland (TRIP / TRUFF) has a new app called ‘iMicro’
9:31 – Wesana Health Holdings (WESA) begins trading on the CSE

Link to the FDA clearing researchers to test MDMA on themselves:

FDA Clears Researchers To Study MDMA Use By Therapists Being Trained In Psychedelic Medicine

Link to Mindmed’s Q1 2021 Financial report and business highlights:
https://www.newswire.ca/news-releases/mindmed-announces-2021-q1-financial-results-cash-balance-of-160m-usd-194m-cad-to-execute-on-diverse-clinical-pipeline-816112809.html

Link to Compass Pathways (CMPS) Q1 Financial report:https://www.globenewswire.com/news-release/2021/05/13/2228969/0/en/COMPASS-Pathways-plc-announces-financial-results-and-business-highlights-for-the-first-quarter-2021.html

Link to Numinus (NUMI) supplying psilocybin extract to Optimi Health:
https://psilocybinalpha.com/news/numinus-wellness-and-optimi-health-submit-all-natural-psilocybin-extract-to-health-canada-for-pre-clinical-trial-application

Link to Red Light Holland’s (TRIP / TRUFF) new app ‘iMicro’:
https://investingnews.com/news/agriculture-investing/red-light-holland-imicro-digital-care-app-and-telecounseling-goes-live/

Link to Wesana Health Holdings (WESA):
https://psilocybinalpha.com/news/wesana-health-commences-trading-on-the-cse

Image source: https://www.google.com/search?q=mike+tyson&rlz=1C1CHBF_enCA821CA821&sxsrf=ALeKk01FAUv0g0uK0yvLRLlkKOCgPEda6g:1621187634437&source=lnms&tbm=isch&sa=X&ved=2ahUKEwiagcLI4s7wAhWSF1kFHUeECgsQ_AUoAnoECAEQBA&biw=1600&bih=699#imgrc=Hwv5W22HvZQ3QM

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #PsychedelicStocks #CMPS

Similar Posts

  • Dr. Matthew Johnson discusses Psychedelics, the Hard Problem of Consciousness and UFOs

    Listen, Videos

    During our time in Wonderland Miami, we had the pleasure to meet and interview Dr. Matthew Johnson of Johns Hopkins University. In this Psychedelic Spotlight Interview, we discuss a wide range of topics surrounding psychedelics and their effectiveness as treatments for ailments like tobacco addiction and PTSD. Of course, our conversation took as spin as we also touched on topics such as UFOs, DMT experiences and the CIA!

    Timestamps:

    0:00 – Intro
    1:10 – Dr. Johnson’s latest updates on treating smoking cessation with psilocybin
    6:55 – MAPS’ study using MDMA to treat PTSD
    7:20 – DMT’S mystical experiences of perceiving aliens, machine elves and autonomous beings
    13:08 – CIA research on psychedelics for telepathy and remote viewing
    15:01 – What is consciousness?
    19:02 – The intriguing evidence of UFOs?
    21:40 – Where do we see psychedelics going in the next 5 years?

    Make sure to like, share and subscribe if you enjoyed this episode!

    #Psychedelics #MatthewJohnson #UFO

  • Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES!

    Listen, Videos

    Can Psychedelics Treat Alcoholism? New Psilocybin & DMT Studies Say YES

    Wakeful Travel Kickstarter: https://www.kickstarter.com/projects/920110985/wakeful-travel-journals-support-your-transformation?ref=f1y202

    In today’s episode, we dive into two pre-clinical studies testing psychedelics’ effectiveness in treating alcohol-related illnesses.

    In the first, researchers tested psilocybin (magic mushrooms) on mice who got addicted to alcohol. They found that the psilocybin helped repair a part of their brain that alcohol abuse damaged. This helped the mice make less neurotic decisions, and helped them abstain from alcohol.

    This is promising, and if it can be repeated in humans, it would be a huge step forward in treating alcoholism.

    The second study looked at the Ayahuasca brew, which has as its main psychoactive ingredient DMT. In this study, the researchers found that the mice who took the ayahuasca were less likely to seek out more alcohol.

    Again, if this can be replicated in humans, it would show the powerful benefits of psychedelic medicines to treat alcoholism.

    Psychedelics and mental health have long been a topic of research, and we are finally getting data that psychedelics like psilocybin and DMT may be effective in treating a variety of mental health conditions, such as alcoholism.

    Links:
    Psilocybin Study
    https://www.science.org/doi/10.1126/sciadv.abh2399#F5

    Psilocybin article
    https://www.inverse.com/mind-body/psilocybin-repairs-alcohol-brain-damage

    Ayahuasca study:
    https://pubmed.ncbi.nlm.nih.gov/34822961/

    Enjoy the episode!
    Follow us on social media!
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor
    James’ Twitter: @Psy_Invest
    Maria’s Twitter (Producer & Editor): @Psy_Holy

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com
    Video editing: @themyaholy

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Psilocybin #DMT #Psychedelics

  • Will MindMed (MMED) join the NASDAQ? (What Will Happen To the Stock If It Does?)

    Listen, Videos

    Will MindMed get uplisted on the NASDAQ and what will happen to its stock price if the company is accepted? These are all questions we’ve been wondering 😱.

    The requirements to join NASDAQ have been less than clear for investors. It has been more than six weeks since MindMed (MMED) applied for an uplisting on NASDAQ and retail investors have been waiting for news while MindMed’s stock price has been reaching all times highs🔥. In this video, we’ll discuss what the actual requirements are, what will happen to MMED’s stock price if the company gets uplisted, and whether retail investors should be influenced by the news ( good or bad).

    Hope you guys enjoy this video!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed #mmed #mindmedstock
    Resources: https://www.thestreet.com/investing/nasdaq-listing-requirements-15092402?fbclid=IwAR09DXpV8nLoMgXrJ7Ru1A8GHk53BHQBakLFI1xnHLw-ZDzY7nZjp88D0CU

  • BIG MindMed MDMA Trial, Atai to Compete with Elon’s Neuralink ? (+ Updates on CMPS, MYCO and ENBI)

    Listen, Videos

    Hey Psychedelic Investors! There’s been so much news this week that we decided to split “This Week In Psychedelic Stocks” in 2 parts. Part Deux: ” BIG MindMed MDMA Trial, Atai’s to Compete with Tesla’s Neuralink (+Updates on CMPS, MYCO and ENBI)” might be a lot more interesting to some of you, however, I would suggest you watch Part I entitled: “HUGE Studies Released: Psychedelics About to TAKE OVER the Stock market?” That is if you are interested in the general developments in the psychedelic industry for this week.

    In this episode, there’s lots of news for the psychedelic industry writ large. We’ll start up with three different studies that were released in the first week of April.

    1. We’ll cover some MindMed News [ MMED / MMEDF recently announced a new MDMA study ]
    2. Atai Life Sciences’ Computer Brain Interface & their clinical trial to treat Schizophrenia
    3. Compass Pathways (CMPS) has amazing new price targets
    4. Mydecine (MYCO / MYCOF ) has progressed four new compounds towards clinical trials
    5. Entheon’s (ENBI / ENTBF) new Genetic Test Kit Updates

    ​…
    ​Timestamps:
    0:00​ – Intro
    1:47 – MindMed’s (MMED / MMEDF / MMQ) Announcing New Data on Personalized MDMA Dosing
    6:08 – Atai Life Sciences acquires Psyber Inc to develop Brain Computer Interface -enabled digital therapeutics targeting mental health disorder
    8:00 – Atai’s Subsidiary, Recognify Life Sciences, to Commence Phase 2 clinical study in Cognitive Impairment associated with Schizophrenia
    9:07 – Roth Capital Upgrades Compass Pathways (CMPS) price targets & CMPS has scheduled a corporate update
    10:32 – Mydecine ( MYCOF / MYCO ) Announces Four New Lead Drug Candidates for Pre-IND Meetings with the FDA & Health Canada to prepare for clinical trials. ( MYCO 001, MYCO 002, MYCO 003 & MYCO 004 )
    13:02 – Entheon Biomedical (ENBI / ENTBF ) has now launched Halugen’s Psychedelics’ Genetic KIT
    So that’s it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this! As our thumbnail titles states: The SHROOM BOOM is REAL! Psychedelics are taking the world by storm and psychedelic inspired companies are releasing news every single day. We’ll try to cover most of them but if there’s a company you want us to cover more in debt, please let us know in the comments and we’ll try to satisfy your demands.

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor

    If you want to collaborate shoot us an email at: thepsychedelicinvestor@gmail.com

    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifa
    ​…
    ​
    https://benzinga.grsm.io/thepsychedel

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​​​ ​#MMEDStock #CMPS Stock

  • 4 NEW Psychedelics Trial Updates in 1 Day | Psilocybin, LSD, 18MC + Microdosing [MNMD, CMPS, FH]

    Learn, Videos

    Whether or not psychedelic medicines will become legalized to treat patients with mental health conditions will ultimately rest on whether clinical trials treating conditions with compounds like psilocybin are successful.

    This is why today’s news is so exciting. We got updates on four separate clinical trials.
    First, is new data from a phase 1 clinical trial using Compass Pathways (Nasdaq: CMPS) Comp360 psilocybin. This trial added to the growing data showing that large doses of psilocybin are safe to take. It also showed no negative cognitive side effects of taking the drug.

    Next, we got updates on two MindMed (Nasdaq: MNMD, NEO: MMED) trials. First, we found out about a new phase 1 trial which will combine LSD with SSRIs. This will be important, because we need to know whether mental health patients with disorders like major depressive disorder can remain on their prescriptions when undergoing psychedelic therapy.

    Next, MindMed announced that their phase 1 clinical trial attempting to treat addiction with 18-MC, a proprietary non-hallucinogenic version of ibogaine, was completed. We should expect data relatively soon, and a phase 2a trial to begin shortly after.

    Finally, we learned of a new microdosing trial that is set to begin at the University of Toronto. This phase 2 trial will test treating persistent depressive disorder using psilocybin microdoses. The psilocybin is Filament Health’s (OTCQB:FLHLF, NEO:FH) version of psilocybin, making it an important step for this company.

    For investors in psychedelic stocks, and those who just want to see better mental health care treatments alike, this was a big week. Hopefully, as time progresses, we will start getting data back from these trials and the shroom boom will go into full force!

    Can psychedelics treat mental health conditions? Can microdosing help depression? Can you keep taking antidepressants while taking LSD? Today, we became a step closer to answering all of these questions!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy
    @Psychedelic Spotlight

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #Microdosing #Psilocybin

  • California COWARDS Delay Psychedelics Decriminalization Bill (I’m Pissed)

    Listen, Videos

    What’s up psychedelic investors! Today’s episode is mostly a RANT about how the California cowards delayed the psychedelics decriminalization bill until NEXT YEAR, their reason being that their LEADERS ARE NOT “EDUCATED” enough on the matter at hand…😤

    Enjoy my 11 minute rant!

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #californiapsychedelicsbill #californiabill #psychedelicstocks